Gusacitinib
Gusacitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase SYK and tyrosine-protein kinase JAK2.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Basal cell nevus syndrome | D001478 | EFO_0004136 | 2 | 3 | — | — | — | 3 | |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | 2 | — | — | — | 3 |
| Basal cell neoplasms | D018295 | — | 1 | — | — | — | 1 | ||
| Basal cell carcinoma | D002280 | 1 | 1 | — | — | — | 1 | ||
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | 1 | — | — | — | 1 |
| Neoplasms | D009369 | C80 | 1 | 1 | — | — | — | 1 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | 1 | — | — | — | 1 | |
| Primary myelofibrosis | D055728 | D47.4 | 1 | 1 | — | — | — | 1 | |
| Lymphoma | D008223 | C85.9 | 1 | 1 | — | — | — | 1 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Eczema | D004485 | HP_0000964 | L30.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GUSACITINIB |
| INN | gusacitinib |
| Description | Gusacitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase SYK and tyrosine-protein kinase JAK2. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1425381-60-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594275 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 4801QYW816 (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 43 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
43 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more